Evidence map›Paper›PMID 42304060›Full record

ArticleScientific reports2026

A 5mC-related gene signature predicts prognosis and therapy response in hepatocellular carcinoma.

Shaohua Xu, Xuedong Niu, Changlin Zhang, Qianyuan Li, Chunhua Luo, Jun Yan

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shaohua Xu *Department of Clinical Laboratory Medicine, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, Hubei, China. shxu2021@whu.edu.cn.
Xuedong Niu *The First College of Clinical Medical Science, China Three Gorges University, Yichang, 443000, Hubei Province, China.
Changlin ZhangDepartment of Clinical Laboratory Medicine, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, Hubei, China.
Qianyuan LiDepartment of Clinical Laboratory Medicine, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, Hubei, China.
Chunhua LuoDepartment of Clinical Laboratory Medicine, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, Hubei, China.
Jun YanThe First College of Clinical Medical Science, China Three Gorges University, Yichang, 443000, Hubei Province, China. yanjun@ccmu.edu.cn.

Funding

The Doctoral Start-up Foundation of Yichang Central People's Hospital 2024BS004385
6 · The paper itself

Abstract

Increasing evidence has highlighted the biological significance of 5-methylcytosine (5mC) DNA modification in regulating tumorigenesis and cancer progression. However, the potential roles of the 5mC modification in HCC are still unknown. A consensus clustering algorithm was performed to determine 5mC modification patterns and establish a 5mC-related gene signature in HCC. Weighted gene co‑expression network analysis (WGCNA) integrated with machine learning approaches (LASSO, RF, and SVM‑RFE) was applied to identify candidate biomarkers, and a 5mC risk score model was subsequently constructed. The concordance index (C‑index), decision curve analysis (DCA), and ROC curve were employed to evaluate the performance of the nomogram. Two distinct 5mC modification patterns were identified, with cluster B exhibiting worse prognosis and enrichment of cell cycle and metabolic pathways. Using integrated WGCNA and machine learning, we constructed a three-gene (DNMT1, SPATS2, MCM6) risk score model that effectively stratified patients into high- and low-risk groups with significantly different overall survival. The risk score demonstrated robust prognostic performance across independent cohorts and was an independent prognostic factor. High risk scores correlated with advanced stage, higher tumor mutational burden, distinct immune microenvironment features, and increased sensitivity to multiple chemotherapeutic and targeted agents. A nomogram incorporating the risk score and clinicopathological features showed acceptable predictive accuracy and clinical net benefit. Experimental validation confirmed upregulation of DNMT1 and SPATS2 in HCC tissues, and their knockdown suppressed HCC cell proliferation, migration, and invasion. The 5mC risk model demonstrates clinical applicability and net benefit in terms of prognostic stratification, immunophenotype characterization, and prediction of drug therapy response in HCC patients, providing a useful tool for precision oncology.

Indexed as

5-MethylcytosineCarcinoma, HepatocellularLiver NeoplasmsBiomarkers, TumorDNA (Cytosine-5-)-Methyltransferase 1DNA MethylationFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMachine LearningMaleMiddle AgedNomogramsPrognosis5-MethylcytosineBiomarkers, TumorDNA (Cytosine-5-)-Methyltransferase 1DNMT1 protein, human5-methylcytosineDNMT1Hepatocellular CarcinomaSPATS2SVM-RFEWGCNA

Identifiers

PMID42304060
PMCPMC13354768

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.